4.6 Article

Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry

期刊

INFECTION
卷 50, 期 5, 页码 1191-1202

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s15010-022-01792-0

关键词

Infective endocarditis; Elderly; Prognosis; Surgery; Propensity analysis

资金

  1. Abbott Vascular Int.
  2. Amgen Cardiovascular
  3. AstraZeneca
  4. Bayer AG
  5. Boehringer Ingelheim
  6. Boston Scientific
  7. Bristol Myers Squibb
  8. Pfizer Alliance
  9. Daiichi Sankyo Europe GmbH
  10. Alliance Daiichi Sankyo Europe GmbH
  11. Eli Lilly and Company
  12. Edwards
  13. Gedeon Richter Plc.
  14. Menarini Int. Op.
  15. MSD-Merck Co.
  16. Novartis Pharma AG
  17. ResMed
  18. Sanofi
  19. SERVIER
  20. Vifor

向作者/读者索取更多资源

In octogenarians with infective endocarditis, valvular surgery is less frequently indicated and performed, resulting in higher in-hospital and 1-year mortality rates. Age itself is not a predictor of mortality, but lack of surgical intervention when indicated strongly predicts poorer outcomes.
Purpose High mortality and a limited performance of valvular surgery are typical features of infective endocarditis (IE) in octogenarians, even though surgical treatment is a major determinant of a successful outcome in IE. Methods Data from the prospective multicentre ESC EORP EURO-ENDO registry were used to assess the prognostic role of valvular surgery depending on age. Results As compared to < 80 yo patients, >= 80 yo had lower rates of theoretical indication for valvular surgery (49.1% vs. 60.3%, p < 0.001), of surgery performed (37.0% vs. 75.5%, p < 0.001), and a higher in-hospital (25.9% vs. 15.8%, p < 0.001) and 1-year mortality (41.3% vs. 22.2%, p < 0.001). By multivariable analysis, age per se was not predictive of 1-year mortality, but lack of surgical procedures when indicated was strongly predictive (HR 2.98 [2.43-3.66]). By propensity analysis, 304 >= 80 yo were matched to 608 < 80 yo patients. Propensity analysis confirmed the lower rate of indication for valvular surgery (51.3% vs. 57.2%, p = 0.031) and of surgery performed (35.3% vs. 68.4%, p < 0.0001) in >= 80 yo. Overall mortality remained higher in >= 80 yo (in-hospital: HR 1.50[1.06-2.13], p = 0.0210; 1-yr: HR 1.58[1.21-2.05], p = 0.0006), but was not different from that of < 80 yo among those who had surgery (in-hospital: 19.7% vs. 20.0%, p = 0.4236; 1-year: 27.3% vs. 25.5%, p = 0.7176). Conclusion Although mortality rates are consistently higher in >= 80 yo patients than in < 80 yo patients in the general population, mortality of surgery in >= 80 yo is similar to < 80 yo after matching patients. These results confirm the importance of a better recognition of surgical indication and of an increased performance of surgery in >= 80 yo patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据